



PRESS RELEASE

Published: 2025-09-17

Inhalation Sciences launches marketing campaign to increase awareness

Inhalation Sciences Sweden AB (ISAB or the company) today announces the start of a marketing campaign with the goal of increasing awareness and interest of its platform technology and cutting-edge services within inhaled drug development. The campaign will be implemented primarily via LinkedIn, the company's website as well as in industry meetings and is designed to reach key stakeholders across the pharmaceutical industry as well as contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs).

The campaign is based on two important drivers: the regulatory tailwind that is currently benefiting ISAB's platform technology, PreciseInhale[®] and the unique results that have been demonstrated in the FDA-funded study of the DissolvIt[®] module. The results of the study, to be presented at the Drug Delivery to the Lungs (DDL) conference in December 2025, shows that DissolvIt[®] demonstrates strong potential to generate data that enhances the prediction of clinical plasma profiles. These findings represent a significant advancement for inhaled drug development programs.

The awareness campaign will highlight several trends that are accelerating the need for high-resolution data and predictability.

- Increased interest in inhalation as a route of administration
- Shift to green, low-Global Warming Potential (GWP) propellants
- Increasing focus on inhaled biologics
- Accelerated regulatory processes for generics and biologics
- FDA and EMA's new recommendations on dissolution testing and spray characterization
- FDA's planned phase-out of animal testing

"Through our awareness campaign, we will highlight both the regulatory drivers and the results from the DissolvIt study. It positions our services as not only unique, but also strategically aligned with where the industry is headed. An important purpose is to build interest and visibility ahead of the DDL conference, where we can meet the industry with new data and further strengthen our position in the market," says Ulf Wedenberg, Chief Commercial Officer at Inhalation Sciences.

For more information, please contact:

Manoush Masarrat, CEO

Phone: +46 (0) 73 628 9153

E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.